Merck & Co. (MRK)
(Delayed Data from NYSE)
$118.45 USD
+0.99 (0.84%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $118.28 -0.17 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Merck (MRK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$139.83 | $155.00 | $125.00 | 18.05% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for Merck comes to $139.83. The forecasts range from a low of $125.00 to a high of $155.00. The average price target represents an increase of 18.05% from the last closing price of $118.45.
Analyst Price Targets (23)
Broker Rating
Merck currently has an average brokerage recommendation (ABR) of 1.23 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 26 brokerage firms. The current ABR compares to an ABR of 1.24 a month ago based on 25 recommendations.
Of the 26 recommendations deriving the current ABR, 23 are Strong Buy, representing 88.46% of all recommendations. A month ago, Strong Buy represented 88%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/MRK.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 23 | 23 | 22 | 21 | 21 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.23 | 1.23 | 1.24 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/8/2024 | Berenberg Bank | Luisa Hector | Strong Buy | Strong Buy |
8/6/2024 | Daiwa America | Narumi Nakagiri | Strong Buy | Strong Buy |
7/31/2024 | Wells Fargo Securities | Mohit Bansal | Hold | Hold |
7/31/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
7/31/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
7/31/2024 | UBS | Colin N Bristow | Strong Buy | Strong Buy |
7/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/30/2024 | Evercore Partners | Umer Raffat | Not Available | Strong Buy |
7/19/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
7/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/16/2024 | Goldman Sachs | Chris Shibutani | Strong Buy | Strong Buy |
6/5/2024 | Not Identified | Not Identified | Hold | Hold |
6/5/2024 | Argus Research Corp. | Jasper Hellweg | Not Available | Strong Buy |
6/4/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
5/15/2024 | Atlantic Equities | Steven K Chesney | Strong Buy | Strong Buy |
4/26/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Steve M Scala | Strong Buy | Strong Buy |
1/29/2024 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
1/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.23 |
ABR (Last week) | 1.23 |
# of Recs in ABR | 26 |
Average Target Price | $139.83 |
LT Growth Rate | 9.00% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | 1.72 |